What is pseudomyxoma peritonei?
Pseudomyxoma peritonei (PMP) is a rare condition in which jelly-like mucus slowly builds up inside the abdomen. The mucus is made by tumour cells that have spread onto the peritoneum, the thin lining of the abdominal cavity. It is sometimes called “jelly belly”.
In almost all cases, PMP starts from a mucinous tumour of the appendix that has burst (perforated). This lets mucus-producing cells escape and settle throughout the abdomen (Carr et al., 2016).
PMP is very rare, affecting roughly 1-2 people per million each year (Smeenk et al., 2008). It is diagnosed two to three times more often in women, partly because it can first appear as an ovarian mass. The average age at diagnosis is around 50-55 years.
Most PMP is low grade. It grows slowly and rarely spreads through the blood to other organs, but if untreated, the mucus gradually fills the abdomen and presses on the bowel and other organs.
The main treatment is cytoreductive surgery (CRS) with heated chemotherapy inside the abdomen (HIPEC), carried out at specialist centres. Many people treated this way live for many years, and a large proportion are cured (Chua et al., 2012).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of condition | Mucinous tumour spread within the abdomen (peritoneum) |
| Usual origin | Ruptured low-grade appendiceal mucinous neoplasm (LAMN) |
| How common | About 1-2 new cases per million people each year |
| Typical age | Around 50-55 years; diagnosed more often in women |
| Key symptoms | Gradually swelling abdomen, new hernia, tummy discomfort |
| Main tests | CT scan, tumour markers (CEA, CA19-9, CA125), biopsy or surgery |
| Main treatment | Cytoreductive surgery plus HIPEC at a specialist centre |
| Outlook | Good for low-grade disease with complete surgery: about 70% alive at 10 years |
2. Causes and origin
PMP develops step by step:
| Step | What happens |
|---|---|
| 1. Appendix tumour | A mucus-producing tumour grows in the appendix, most often a LAMN |
| 2. Swelling and rupture | The appendix fills with mucus, swells (mucocele) and bursts |
| 3. Spread of cells | Tumour cells and mucus escape into the abdomen |
| 4. Redistribution | Fluid circulates and cells settle in typical places: under the diaphragm, in the pelvis, on the omentum (fatty apron) |
| 5. Build-up | Over months to years, the mucus accumulates and the abdomen swells |
The bowel surface itself is often spared for a long time, because it keeps moving. This is called the redistribution phenomenon.
Less common origins
| Origin | Notes |
|---|---|
| Ovary | Rare; usually linked to a mucinous tumour arising in an ovarian teratoma |
| Colon or rectum | Mucinous adenocarcinomas; behave more aggressively |
| Other sites | Urachus, pancreas, stomach; very rare |
In women with PMP and an ovarian mass, the ovary is usually a secondary site and the true origin is still the appendix.
Risk factors
No clear lifestyle risk factors are known. PMP is not inherited and not infectious. Some appendiceal tumours carry gene changes such as KRAS and GNAS, but these arise in the tumour only.
3. Types (grades) of PMP
Pathologists classify PMP using the PSOGI system (Carr et al., 2016).
| Type | Description | Behaviour |
|---|---|---|
| Acellular mucin | Mucus without tumour cells | Lowest risk |
| Low-grade mucinous carcinoma peritonei | Few, bland tumour cells in a lot of mucus (formerly DPAM) | Slow-growing |
| High-grade mucinous carcinoma peritonei | More cells, more abnormal (formerly PMCA) | Faster-growing |
| High-grade with signet ring cells | Contains signet ring cells | Most aggressive |
The grade is one of the most important factors for treatment planning and outlook.
4. How does it look
On scans
| Feature | Description |
|---|---|
| Fluid | Low-density, jelly-like material throughout the abdomen |
| Scalloping | Mucus pressing on and indenting the surface of the liver and spleen (a classic sign) |
| Omental cake | Thickened fatty apron, filled with tumour |
| Appendix | A swollen appendix or mucocele, sometimes with calcification |
| Ovaries | Cystic masses in some women |
| Distribution | Under the diaphragm, in the pelvis and around the liver, with the small bowel often relatively spared |
At surgery
Surgeons find thick, yellow-white or grey jelly filling parts of the abdomen. It coats organ surfaces and can form large, firm masses, especially in the omentum and pelvis.
Under the microscope
Pathologists see pools of mucus containing strips of mucin-producing tumour cells. The number and appearance of these cells determine the grade.
Visible signs
The most noticeable sign is a gradually enlarging abdomen, sometimes mistaken for weight gain. Some people develop a new hernia in the groin or belly button.
5. Symptoms
PMP often causes few symptoms for a long time. It may be found by chance during surgery for appendicitis or a hernia, or on a scan done for another reason.
Common symptoms
- Swelling of the abdomen, increasing over months or years
- Feeling bloated or full quickly after eating
- Tummy discomfort or vague pain
- A new hernia, especially in the groin (inguinal) or at the belly button
- Symptoms like appendicitis: pain in the lower right abdomen
- Changes in bowel habit
- Weight loss despite a growing tummy (in more advanced disease)
- Tiredness
Symptoms in women
| Finding | Notes |
|---|---|
| Ovarian mass | Found on examination or scan; may be the first sign |
| Pelvic pain | From ovarian or pelvic deposits |
| Raised CA125 | Can suggest ovarian cancer, delaying the correct diagnosis |
Advanced symptoms
| Symptom | Cause |
|---|---|
| Bowel blockage | Mucus and tumour pressing on the bowel; vomiting, cramping, constipation |
| Breathlessness | Pressure on the diaphragm |
| Poor appetite and malnutrition | Pressure on the stomach and bowel |
When to seek medical advice
See a doctor if your abdomen is steadily getting bigger without explanation, you develop a new hernia, or you have persistent bloating or tummy pain.
Seek urgent help for vomiting with a swollen tummy or if you cannot pass wind or stools.
6. Diagnosis
| Test | Purpose |
|---|---|
| CT of the chest, abdomen and pelvis | Main scan; shows the extent and pattern of mucus |
| MRI | Sometimes used to assess the small bowel and pelvis |
| Tumour markers | CEA, CA19-9 and CA125; raised levels help with planning and follow-up |
| Biopsy or surgery | Confirms mucinous tumour and its grade |
| Colonoscopy | Rules out a bowel cancer origin |
| Laparoscopy | Sometimes used to estimate whether complete surgery is possible |
| Expert review of pathology | Recommended for all patients |
Peritoneal cancer index (PCI)
Surgeons score the amount of disease using the peritoneal cancer index, which divides the abdomen into 13 regions and scores each from 0 to 3, giving a total of 0 to 39. A higher score means more extensive disease and more complex surgery.
Conditions that can look similar
| Condition | How it differs |
|---|---|
| Ovarian cancer | Different tumour type; usually high CA125 and solid masses |
| Peritoneal mesothelioma | Arises from the lining itself; not mucinous |
| Peritoneal spread from bowel or stomach cancer | More aggressive; solid nodules |
| Ascites from liver disease | Thin fluid, not jelly; no tumour cells |
7. Treatment
PMP is treated at national or specialist peritoneal malignancy centres, because the surgery is complex and results are best in experienced hands (Govaerts et al., 2021).
Cytoreductive surgery (CRS)
The aim is to remove all visible tumour and mucus. This is often a long operation, sometimes lasting 8-12 hours.
| Part of surgery | What may be removed |
|---|---|
| Peritoneum | Affected areas of the abdominal lining (peritonectomy) |
| Omentum | The fatty apron, often heavily involved |
| Appendix and right colon | The origin of the tumour |
| Spleen and gallbladder | If involved |
| Ovaries and uterus | In women, if involved |
| Parts of the bowel or stomach | If needed to clear disease |
HIPEC
After all visible tumour is removed, heated chemotherapy (HIPEC), usually mitomycin C, is circulated inside the abdomen for about 60-90 minutes. The heat helps the drug kill remaining microscopic tumour cells. A multisocietal consensus supports CRS with HIPEC as the standard treatment for PMP of appendiceal origin (Kusamura et al., 2025).
When complete removal is not possible
| Approach | Purpose |
|---|---|
| Maximal tumour debulking | Removes as much mucus and tumour as safely possible to relieve symptoms and extend life |
| Repeat surgery | Sometimes possible later if disease builds up again |
| Systemic chemotherapy | Mainly for high-grade or signet ring cell disease; similar to bowel cancer chemotherapy |
| Supportive care | Nutrition, symptom control and stoma care if needed |
Early-stage appendix tumours
If a LAMN is found before it has ruptured, removing the appendix may be enough, followed by monitoring scans. If only a small amount of mucus is found near the appendix, specialist teams decide between surveillance and CRS with HIPEC.
Recovery after surgery
| Stage | What to expect |
|---|---|
| Intensive or high-dependency care | Usually 1-3 days after surgery |
| Hospital stay | Often 2-3 weeks |
| Feeding | Intravenous nutrition at first, then gradual return to food |
| Stoma | Some people need a temporary or permanent stoma |
| Full recovery | Often 3-6 months |
Possible complications
| Complication | Notes |
|---|---|
| Infection and leaks | From bowel joins (anastomoses) |
| Bleeding and blood clots | Prevented with blood-thinning injections |
| Low blood counts | Caused by mitomycin C |
| Slow bowel recovery | Temporary paralysis of the bowel (ileus) |
| Serious complications | Occur in a minority of patients; risk of death after surgery is low at specialist centres |
8. Outlook (prognosis)
| Group | Approximate outlook |
|---|---|
| All patients treated with CRS and HIPEC (international registry) | About 63% alive at 10 years and 59% at 15 years (Chua et al., 2012) |
| Complete cytoreduction, mostly low-grade (UK series of 1000 patients) | About 87% alive at 5 years and 70% at 10 years (Ansari et al., 2016) |
| Maximal debulking only | Lower, but many people still live several years with good quality of life |
| High-grade or signet ring cell disease | Poorer outlook; higher risk of recurrence |
PMP can come back, sometimes many years later. Some recurrences can be treated with further surgery.
9. Follow-up
| Follow-up | Purpose |
|---|---|
| CT or MRI scans | Usually yearly for many years, more often at first |
| Tumour markers | CEA, CA19-9 and CA125, which may rise before recurrence is visible |
| Clinic reviews | Symptoms, nutrition, weight and recovery |
| Stoma and hernia care | Where relevant |
Follow-up often continues for 10 years or more, because late recurrence is possible (Govaerts et al., 2018).
10. Living with pseudomyxoma peritonei
- Ask to be referred to a specialist peritoneal malignancy centre
- Prepare for surgery: stopping smoking, staying active and good nutrition help recovery
- Build up gradually after surgery; fatigue can last months
- Work with a dietitian, especially if you have had parts of the bowel or stomach removed
- Join patient support groups for people with PMP and appendix cancer
- Keep attending follow-up, even when you feel well
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is PMP cancer? | It is a form of cancer, though most cases are low grade and slow-growing |
| Why was my appendix the cause? | A mucinous appendix tumour burst and spread cells into the abdomen |
| Can PMP spread to other organs? | Low-grade PMP rarely spreads outside the abdomen |
| Will I need a stoma? | Some people do, depending on which parts of the bowel are removed |
| Is it caused by anything I did? | No. There is no known lifestyle cause, and it is not inherited |
| Can I have children after treatment? | It depends on whether the ovaries and uterus were removed; ask about fertility options before surgery |
| Can it be cured? | Yes, many people with low-grade PMP are cured with complete CRS and HIPEC |
| Why did my doctor think I had ovarian cancer? | PMP often affects the ovaries and can raise CA125 |
12. Questions to ask your care team
- What grade is my PMP?
- Am I being treated at a specialist peritoneal centre?
- Is complete cytoreduction likely to be possible?
- What is my peritoneal cancer index?
- Will I need a stoma?
- How long will recovery take, and what follow-up will I need?
Resources
- Ansari, N. et al. (2016) ‘Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours’, European Journal of Surgical Oncology, 42(7), pp. 1035-1041.
- Carr, N.J. et al. (2016) ‘A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) modified Delphi process’, American Journal of Surgical Pathology, 40(1), pp. 14-26.
- Chua, T.C. et al. (2012) ‘Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy’, Journal of Clinical Oncology, 30(20), pp. 2449-2456.
- Govaerts, K. et al. (2018) ‘Single centre guidelines for radiological follow-up based on 775 patients treated by cytoreductive surgery and HIPEC for appendiceal pseudomyxoma peritonei’, European Journal of Surgical Oncology, 44(9), pp. 1371-1377.
- Govaerts, K. et al. (2021) ‘Appendiceal tumours and pseudomyxoma peritonei: literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment’, European Journal of Surgical Oncology, 47(1), pp. 11-35.
- Kusamura, S. et al. (2025) ‘Multisocietal consensus on the use of cytoreductive surgery and HIPEC for the treatment of pseudomyxoma peritonei: a GRADE approach for evidence evaluation and recommendation’, Journal of Surgical Oncology, 132(5), pp. 810-816.
- Smeenk, R.M. et al. (2008) ‘Appendiceal neoplasms and pseudomyxoma peritonei: a population based study’, European Journal of Surgical Oncology, 34(2), pp. 196-201.
- National Cancer Institute (2026) Appendiceal Cancer. Available at: https://www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/rare-digestive-system-tumors/appendiceal-cancer (Accessed: October 2026).
Prepared by the editorial team, October 2026.